Movement on the market reflected at CPhI Worldwide 20183 Oct 2018
Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.
Each year, CPhI Worldwide affords the pharmaceutical industry the opportunity to come together to share and learn. Each year, new exhibitors use the event as a platform to showcase their products and services, which frequently mirror trends in customer demand and regulatory requirements.
Making the intolerable, tolerable
Anemia is one of the most widespread diseases in the world and more than 50% of the cases are due to iron deficiency. To recover iron deficiency, however, oral iron products are generally problematic for many patients who are unlikely to tolerate iron and, therefore, are forced to drop out the treatment or to resort to complicated, intravenous administration.
Pharmanutra’s SiderAL products, however, are based on patented Sucrosomial Iron and offer higher tolerability and bioavailability compared with traditional iron-based products. Thanks to its unique delivery system, SiderAL is considered by many as the most effective and innovative oral iron supplement on the market.
The SiderAL range of products includes several formulations, developed to comply with the different nutritional requirements for children, men and women, who need to boost their iron status, reduce fatigue and improve their quality of life.
Migraine is an extraordinarily prevalent neurological disease and the third most prevalent illness in the world. For many migraine suffers, current antimigraine drugs are not tolerated or contraindicated.
To fulfil the unmet needs of migraine medications, Cefaly Technology offers an evidence-based e-TNS (external Trigeminal Nerve Stimulation) device indicated to treat and prevent migraine. The device’s efficacy/safety profile is excellent, exceeding many antimigraine medication.
The Cefaly — a battery-powered device applied on the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve — generates precise electrical impulses allowing to stimulate the trigeminal nerve.
Outsourcing going green
The destructive effect of chlorofluorocarbon refrigerants on the ozone layer is well known. Concern, however, is not limited to CO2 but includes all fluorinated refrigerants and their global warming potential (GWP).
Many gases generated as the result of human activity are more harmful than CO2. Therefore, a gas’s GWP must also be considered as well as the gas quantity released into the atmosphere. European and national regulations controlling the emission of these gases greatly affect industries requiring freeze drying, as the fluorinated refrigerants used in their thermal systems have a high GWP.
As experts in freeze-drying equipment and associated regulatory requirements, CoolVacuum designs and manufactures freeze dryers for numerous sectors. The company offers customers customized solutions, ranging from developing projects for new processes to improving existing one.
CDMOs are becoming more diverse and innovative in their product and service offerings. In response to current trends in and customer demand for products using ‘natural’ and ‘ethical’ ingredients, Farmaceutici Procemsa has launched the first products developed following a new ‘Green & Tech’ philosophy, which combines the ancient phytotherapeutic tradition with technological innovation.
At this year’s CPhI, the company will be offering for the first time an original proposal in the dermocosmetic sector - an innovative gel cream to treat skin imperfections associated with cellulite. The product, which provides a thermogenic action, contains a complex of an Alfalfa (Medicago sativa) extract titrated in a defined tripeptide combined with melatonin.
Rubber and plastic
Sanok RC is a dynamically developing manufacturer of rubber stoppers for use in pharmacy and veterinary medicine. The excellent quality of rubber compounds can be used in a wide range of applications for different types of preparations — antibiotics, infusion fluids, insulin, blood and blood products, and lyophilization — and are made to GMP white zone standards together with a high level of molecular and microbiological purity.
With an openness to specific customer requirement, the company can execute new projects; that is, the preparation of recipes and the implementation of new structural solutions.
Building on the success of having established long-term co-operative relationships with 50% of the top-100 pharmaceutical manufacturers of mist spray medicines in China, Xinjitai (XJT) has decided the time is right to move beyond its domestic market and showcase its products at CPhI Worldwide.
The company focusses on manufacturing plastic metered mist sprayers (pumps), such as nasal sprayers, throat or oral sprayers, and topical sprayers. Unlike many other suppliers, all XJT sprayers do not contain polyoxymethylene (POM) or rubber; instead, the company uses polypropylene (PP) and polyethylene (PE).
Brexit - the EU FMD's painful problem
7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.Read more
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
27 Jan 2019
New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.Read more
New API screening program strengthens Particle Sciences' nanomilling offering
22 Jan 2019
Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.Read more
Univercells introduces breakthrough vaccine manufacturing platform
13 Jan 2019
The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.Read more
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
One month on: medical cannabis is still taboo despite change in law
11 Dec 2018
Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.Read more
EU FMD - time is running out!
13 Nov 2018
Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
DSCSA one-month countdown!
30 Oct 2018
With only a month to go, it really is too late to start trying to develop an in-house solution.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation